Companies › Ascendis Pharma Oncology Division
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TransCon IL-2 β/γ IL-2 receptor agonist with extended half-life via TransCon technology | IL2 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| TransCon TLR7/8 Agonist TLR7/8 agonist with extended half-life via TransCon technology | TLR7, TLR8 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05081609 | TransCon IL-2 β/γ | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2027 |
| NCT05081609 | TransCon TLR7/8 Agonist | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.